Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Veracyte, Inc.

< Previous 1 2 3 4 5 6 Next >

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

February 01, 2023

From Veracyte, Inc.

Via Business Wire

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

December 15, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Third Quarter 2022 Financial Results

November 02, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

November 01, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

October 27, 2022

From Veracyte, Inc.

Via Business Wire

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

October 25, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

October 24, 2022

From Veracyte, Inc.

Via Business Wire

New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

October 18, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

October 13, 2022

From Veracyte, Inc.

Via Business Wire

New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

September 22, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

September 13, 2022

From Veracyte, Inc.

Via Business Wire

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

September 11, 2022

From Veracyte, Inc.

Via Business Wire

New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

September 07, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 01, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

August 31, 2022

From Veracyte, Inc.

Via Business Wire

New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

August 29, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

August 11, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Second Quarter 2022 Financial Results

August 02, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

July 20, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

July 14, 2022

From Veracyte, Inc.

Via Business Wire

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

July 13, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year

June 27, 2022

From Veracyte, Inc.

Via Business Wire

New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

June 20, 2022

From Veracyte, Inc.

Via Business Wire

Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression

June 03, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

May 31, 2022

From Veracyte, Inc.

Via Business Wire

New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

May 26, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

May 26, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Present at Upcoming Investor Conferences

May 26, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

May 16, 2022

From Veracyte, Inc.

Via Business Wire

Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer

May 12, 2022

From Veracyte, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.